Tarextumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTarextumab
Drug Alias NameTRXTAnti-Notch 2/3Anti-Notch 2/3 monoclonal antibodyOMP-59R5
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionNeurogenic locus notch homolog protein 3 antagonistsNeurogenic locus notch homolog protein 2 antagonists
TargetsNeurogenic locus notch homolog protein 2Neurogenic locus notch homolog protein 3
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncomed Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia